![]() INA100012190 and is in the services and/or products, related to all kind of financial/ financial technology services, by using technology or otherwise, including but not limited to wealth management, financial technologies, investment advisory services, financial advice, financial analytics, distribution services and financial information.įinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).įinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) : is the holding Company which is registered with Securities Exchange Board of India as an investment advisor under SEBI (Investment Advisors) Regulations, 2013 (“IA regulations”) vide registration no. The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. ![]() The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. was incorporated in 1999 and is headquartered in Rockville, Maryland.Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was formerly known as Panacea Pharmaceuticals, Inc. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. ![]() It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |